201 results on '"Carrascosa, JM"'
Search Results
2. Recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología sobre el manejo del paciente de edad avanzada con psoriasis en placas moderada-grave
3. Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave
4. BIOBADATOP: Registro Español de Dermatitis Atópica. Descripción y primeros resultados
5. [Translated article] Implementation of Recommendations for the Management of Psoriasis During Preconception, Pregnancy, Postpartum, Breastfeeding, and Perinatal Care
6. HTA3 The Clinical and Economic Value of a Sustained Response in the Treatment of Moderate-to-Severe Psoriasis in Spain: The PSOVALUE Project
7. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM
8. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
9. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
10. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM
11. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey
12. A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?
13. Patient Journey in Atopic Dermatitis: The Real-World Scenario
14. Lymphocyte subpopulations analysis in psoriatic patients treated with biological drugs
15. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
16. Baricitinib for the treatment of atopic dermatitis
17. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
18. Spotlight on Topical Long-Term Management of Plaque Psoriasis
19. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
20. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
21. Prospective observational study to evaluate the benefits for the patient associated with the treatment of plaque psoriasis with apremilast after other systemic treatments in conditions of clinical practice in Spain (APPROPRIATE study)
22. Treatment Appraisal Reports: Usefulness and Transparency
23. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
24. Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial
25. The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis
26. Apremilast for psoriasis treatment
27. Summary of efficacy, impact on work productivity and activity, and safety of baricitinib in moderate-to-severe atopic dermatitis from two monotherapy phase III trials
28. Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
29. The Use of Apremilast in Psoriasis: A Delphi Study
30. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study
31. Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis (vol 89, pg 301, 2018)
32. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis
33. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management
34. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
35. ECONOMIC IMPACT OF ATOPIC DERMATITIS IN ADULTS: A POPULATION STUDY (IDEA STUDY)
36. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
37. Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy
38. Absolute and relative psoriasis area and severity indices over 1 year of treatment with ixekizumab: A descriptive analysis in patients with moderate-to-severe plaque psoriasis
39. Absolute and relative PASI over 1 year of treatment with ixekizumab (IXE): Descriptive analysis in patients with moderate-to-severe plaque psoriasis
40. Economic Impact Of Atopic Dermatitis In Adults: A Population Study (Idea Study)
41. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice
42. Perfil epidemiológico, clínico, y alérgico en pacientes con psoriasis. Evaluación del Registro Español de Dermatitis de Contacto (REIDAC)
43. Fototerapia, una alternativa para el manejo de la forma crónica de enfermedad del injerto contra huésped (EICH)
44. Budget Impact Analysis of Apremilast on Moderate to Severe Psoriasis In Spain
45. Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain
46. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate:a randomized clinical trial (TRANSIT)
47. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis
48. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting
49. PHS27 - Economic Impact Of Atopic Dermatitis In Adults: A Population Study (Idea Study)
50. Changes in the kinase activity of the insulin receptor account for an increased insulin sensitivity of mammary gland in late pregnancy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.